SCHEMBL25834261

SCHEMBL25834261

C=C1CCN(Cc2ccccc2)C(=O)N1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 2/20 0.71
CRBN Q96SW2 2/20 0.71
L3MBTL1 Q9Y468 1/20 0.49
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
GAA P10253 2/20 0.47
EPHX2 P34913 1/20 0.45
POLB P06746 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP2D6 P10635 1/20 0.44
DRD3 P35462 1/20 0.43
KCNH2 Q12809 1/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
MAPT P10636 1/20 0.42
SIGMAR1 Q99720 1/20 0.41
GRM5 P41594 1/20 0.41
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6827489 0.83 DDB1 (1.00) DDB1CRBNL3MBTL1KMT2AMEN1
SCHEMBL25952623 0.80 GAA (0.48) DDB1CRBNKMT2AMEN1GAA
SCHEMBL7837188 0.76 DDB1 (0.56) DDB1CRBNL3MBTL1KMT2AMEN1
SCHEMBL7389188 0.74 L3MBTL1 (0.73) DDB1CRBNL3MBTL1KMT2AMEN1
SCHEMBL5251522 0.73 MAPT (0.70) DDB1CRBNL3MBTL1KMT2AMEN1
SCHEMBL152680 0.73 MAPT (0.70) DDB1CRBNL3MBTL1KMT2AMEN1
SCHEMBL25834265 0.73 P2RX7 (0.45) POLBKDM4EMAPTSIGMAR1
SCHEMBL8248998 0.72 DDB1 (0.59) DDB1CRBNL3MBTL1KMT2AMEN1
SCHEMBL9850086 0.72 DDB1 (0.69) DDB1CRBNL3MBTL1KMT2AMEN1
SCHEMBL1011633 0.72 DDB1 (0.69) DDB1CRBNL3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226035-A1 SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION CD4, CRBN, GZMB DDB1 3336/4885CRBN 2/4885L3MBTL1 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.